Literature DB >> 28763793

Virion incorporation of integrin α4β7 facilitates HIV-1 infection and intestinal homing.

Christina Guzzo1, David Ichikawa1, Chung Park2, Damilola Phillips1, Qingbo Liu1, Peng Zhang1, Alice Kwon1, Huiyi Miao1, Jacky Lu1, Catherine Rehm3, James Arthos4, Claudia Cicala4, Myron S Cohen5, Anthony S Fauci4, John H Kehrl2, Paolo Lusso6.   

Abstract

The intestinal mucosa is a key anatomical site for HIV-1 replication and CD4+ T cell depletion. Accordingly, in vivo treatment with an antibody to the gut-homing integrin α4β7 was shown to reduce viral transmission, delay disease progression, and induce persistent virus control in macaques challenged with simian immunodeficiency virus (SIV). We show that integrin α4β7 is efficiently incorporated into the envelope of HIV-1 virions. Incorporated α4β7 is functionally active as it binds mucosal addressin cell adhesion molecule-1 (MAdCAM-1), promoting HIV-1 capture by and infection of MAdCAM-expressing cells, which in turn mediate trans-infection of bystander cells. Functional α4β7 is present in circulating virions from HIV-infected patients and SIV-infected macaques, with peak levels during the early stages of infection. In vivo homing experiments documented selective and specific uptake of α4β7+ HIV-1 virions by high endothelial venules in the intestinal mucosa. These results extend the paradigm of tissue homing to a retrovirus and are relevant for the pathogenesis, treatment, and prevention of HIV-1 infection.
Copyright © 2017, American Association for the Advancement of Science.

Entities:  

Year:  2017        PMID: 28763793      PMCID: PMC5653278          DOI: 10.1126/sciimmunol.aam7341

Source DB:  PubMed          Journal:  Sci Immunol        ISSN: 2470-9468


  53 in total

Review 1.  The regulation of integrin function by divalent cations.

Authors:  Kun Zhang; JianFeng Chen
Journal:  Cell Adh Migr       Date:  2012 Jan-Feb       Impact factor: 3.405

2.  Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.

Authors:  Aurelien Amiot; Jean-Charles Grimaud; Laurent Peyrin-Biroulet; Jerome Filippi; Benjamin Pariente; Xavier Roblin; Anthony Buisson; Carmen Stefanescu; Caroline Trang-Poisson; Romain Altwegg; Philippe Marteau; Thibaud Vaysse; Anne Bourrier; Stephane Nancey; David Laharie; Matthieu Allez; Guillaume Savoye; Jacques Moreau; Charlotte Gagniere; Lucine Vuitton; Stephanie Viennot; Alexandre Aubourg; Anne-Laure Pelletier; Guillaume Bouguen; Vered Abitbol; Yoram Bouhnik
Journal:  Clin Gastroenterol Hepatol       Date:  2016-02-22       Impact factor: 11.382

3.  Presence of host ICAM-1 in laboratory and clinical strains of human immunodeficiency virus type 1 increases virus infectivity and CD4(+)-T-cell depletion in human lymphoid tissue, a major site of replication in vivo.

Authors:  Salim Bounou; Jacques E Leclerc; Michel J Tremblay
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

4.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

Review 5.  HIV infection and the gastrointestinal immune system.

Authors:  J M Brenchley; D C Douek
Journal:  Mucosal Immunol       Date:  2008-01       Impact factor: 7.313

6.  Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines.

Authors:  L O Arthur; J W Bess; R C Sowder; R E Benveniste; D L Mann; J C Chermann; L E Henderson
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

Review 7.  Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells.

Authors:  Manol Jovani; Silvio Danese
Journal:  Curr Drug Targets       Date:  2013-11       Impact factor: 3.465

8.  Human herpesvirus 6A accelerates AIDS progression in macaques.

Authors:  Paolo Lusso; Richard W Crowley; Mauro S Malnati; Clelia Di Serio; Maurilio Ponzoni; Angelique Biancotto; Phillip D Markham; Robert C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-14       Impact factor: 11.205

9.  Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry.

Authors:  Raffaello Cimbro; Francis C Peterson; Qingbo Liu; Christina Guzzo; Peng Zhang; Huiyi Miao; Donald Van Ryk; Xavier Ambroggio; Darrell E Hurt; Luca De Gioia; Brian F Volkman; Michael A Dolan; Paolo Lusso
Journal:  EBioMedicine       Date:  2016-06-26       Impact factor: 8.143

10.  CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract.

Authors:  Jason M Brenchley; Timothy W Schacker; Laura E Ruff; David A Price; Jodie H Taylor; Gregory J Beilman; Phuong L Nguyen; Alexander Khoruts; Matthew Larson; Ashley T Haase; Daniel C Douek
Journal:  J Exp Med       Date:  2004-09-13       Impact factor: 14.307

View more
  27 in total

1.  Intestinal CD4 Depletion in HIV / SIV Infection.

Authors:  Ronald S Veazey
Journal:  Curr Immunol Rev       Date:  2019

2.  The V2 loop of HIV gp120 delivers costimulatory signals to CD4+ T cells through Integrin α4β7 and promotes cellular activation and infection.

Authors:  Livia R Goes; Alia Sajani; Aida Sivro; Ronke Olowojesiku; Jocelyn C Ray; Ian Perrone; Jason Yolitz; Alexandre Girard; Louise Leyre; Constantinos Kurt Wibmer; Lynn Morris; Giacomo Gorini; Genoveffa Franchini; Rosemarie D Mason; Mario Roederer; Saurabh Mehandru; Marcelo A Soares; Claudia Cicala; Anthony S Fauci; James Arthos
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-07       Impact factor: 11.205

3.  Exosomal regulation of lymphocyte homing to the gut.

Authors:  Eun Jeong Park; Onmanee Prajuabjinda; Zay Yar Soe; Samuel Darkwah; Michael G Appiah; Eiji Kawamoto; Fumiyasu Momose; Hiroshi Shiku; Motomu Shimaoka
Journal:  Blood Adv       Date:  2019-01-08

4.  Virion-incorporated PSGL-1 and CD43 inhibit both cell-free infection and transinfection of HIV-1 by preventing virus-cell binding.

Authors:  Tomoyuki Murakami; Nancy Carmona; Akira Ono
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-19       Impact factor: 11.205

5.  Nonhuman Primate Models and Understanding the Pathogenesis of HIV Infection and AIDS.

Authors:  Ronald S Veazey; Andrew A Lackner
Journal:  ILAR J       Date:  2017-12-01

6.  Quantitative analyses reveal distinct sensitivities of the capture of HIV-1 primary viruses and pseudoviruses to broadly neutralizing antibodies.

Authors:  Jiae Kim; Ousman Jobe; Kristina K Peachman; Nelson L Michael; Merlin L Robb; Mangala Rao; Venigalla B Rao
Journal:  Virology       Date:  2017-05-31       Impact factor: 3.616

7.  The HIV-1 Antisense Protein ASP Is a Transmembrane Protein of the Cell Surface and an Integral Protein of the Viral Envelope.

Authors:  Yvonne Affram; Juan C Zapata; Zahra Gholizadeh; William D Tolbert; Wei Zhou; Maria D Iglesias-Ussel; Marzena Pazgier; Krishanu Ray; Olga S Latinovic; Fabio Romerio
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

Review 8.  Differentiating Immune Cell Targets in Gut-Associated Lymphoid Tissue for HIV Cure.

Authors:  Shahzada Khan; Sushama Telwatte; Martin Trapecar; Steven Yukl; Shomyseh Sanjabi
Journal:  AIDS Res Hum Retroviruses       Date:  2017-11       Impact factor: 2.205

9.  Mechanistic basis of post-treatment control of SIV after anti-α4β7 antibody therapy.

Authors:  Chad R Wells; Youfang Cao; David P Durham; Siddappa N Byrareddy; Aftab A Ansari; Nancy H Ruddle; Jeffrey P Townsend; Alison P Galvani; Alan S Perelson
Journal:  PLoS Comput Biol       Date:  2021-06-09       Impact factor: 4.475

Review 10.  Targeting the Latent Reservoir for HIV-1.

Authors:  Srona Sengupta; Robert F Siliciano
Journal:  Immunity       Date:  2018-05-15       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.